

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata's lead investigational product candidate, LSTA1 (formerly known as CEND-1), LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment, with the objective of making tumors more susceptible to immunotherapies LSTA1 has demonstrated favorable safety, tolerability, and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, Lisata has clinical development programs based on its autologous CD34+ cell therapy technology platform.

MARKET SNAPSHOT

TICKER SYMBOL	LSTA
EXCHANGE	NASDAQ
52-WEEK PRICE RANGE	\$2.36 - \$11.70
CASH & INVESTMENTS (12/31/2022)	\$69.2 million
FISCAL YEAR-END	December 31

INVESTMENT RATIONALE



Proprietary field-leading technology in underserved global indications backed by a strong IP portfolio



\$69.2 million cash and investments* - no debt; Highly capital efficient development plans funded through critical milestones



Multiple projected potential value creating product and business development events over the next 24 months



Platform technology "validated" by noteworthy existing partnerships with potential for many others



Seasoned management with successful drug development expertise as well as big and emerging pharma experience

* As of 12/31/2022

LSTA1 CAPITAL EFFICIENT DEVELOPMENT PLAN

Development Partner(s) [Development Venue]	Indication and Trial Product/Comparator	Stage of Development	Strategic Rationale
Lisata/AGITG [Australia/New Zealand/Ireland]	First-line mPDAC; Gemcitabine/nab-paclitaxel with LSTA1 or placebo	Phase 2b (ASCEND)	Corroborate Phase 1b results in a placebo-controlled trial and evaluate 2 dose regimens of LSTA1 for dose optimization
Lisata [United States]	Various Solid Tumors; SoC with LSTA1 or placebo	Phase 2a (Basket Trial)	Assess LSTA1 safety and effectiveness in several tumor types in a placebo-controlled trial (Proof-of-Concept)
KUCC/Lisata [United States]	Pancreatic, Colon & Appendiceal Cancers; LSTA1 + FOLFIRINOX + panitumumab*	Phase 1b/2a (CENDIFOX)	Tumor immuno-profiling pre- & post-treatment and LSTA1 effectiveness assessment in combination with chemo and an EGFR inhibitor (open label)
Qilu [China]	First-line mPDAC; Gemcitabine/nab-paclitaxel + LSTA1	Phase 1b/2a	Assess safety, PK and therapeutic effect of LSTA1 in Chinese patients (open label)
WARPINE/Lisata [Australia]	Locally advanced resectable PDAC; Durvalumab/gemcitabine/nab-paclitaxel + LSTA1	Phase 1b/2a (iLSTA)	Assess LSTA1 safety and effectiveness in combination with IO & Chemo in locally advanced PDAC; determine if inoperable tumors can become operable (open label)
WARPINE/Lisata [Australia]	Locally advanced resectable Gastroesophageal (GE) adenocarcinoma; Nivolumab + FFX + LSTA1	Phase 1b/2a (iGoLSTA)	Assess LSTA1 safety and effectiveness in combination with IO & chemo in locally advanced GE AdenoCa; determine if inoperable tumors can become operable (open label)
Tartu University/Lisata [Estonia]	First-line Glioblastoma Multiforme; Temozolomide ± LSTA1	Phase 2a	Assess LSTA1 safety and effectiveness in additional tumor type (GBM) a in placebo-controlled trial
UCSD/Columbia University/Lisata [United States]	Peritoneal Carcinomatosis LSTA+HIPEC intraoperatively	Phase 1b/2a	Assess safety and intraoperative tumor penetration of HIPEC in combination with LSTA1 (open label)
Qilu [China]	First-line mPDAC; Gemcitabine/nab-paclitaxel + LSTA1	Phase 2b	Continue development of LSTA1 in China (placebo controlled)
Roche/Lisata [Multi-national]	First-line mPDAC; Gemcitabine/nab-paclitaxel/LSTA1 ± atezolizumab	Phase 1b/2 (MORPHEUS)	Assess LSTA1 safety and effectiveness in combination with SoC chemotherapy & immunotherapy (controlled trial)

CD34+ CELL THERAPY CURRENT CLINICAL TRIALS

*Legacy development programs provide potential value upside with **no** further capital outlay*

Sponsor [Development Venue]	Indication and Trial Product/Comparator	Stage of Development	Strategic Rationale
Lisata [Japan]	Critical Limb Ischemia & Buerger's Disease; HONEDRA® (LSTA12)	Registration Eligible	Assess safety and efficacy of LSTA12 in a controlled trial vs. SoC alone in the context of qualifying for approval in Japan under the accelerated regulatory pathway applicable to regenerative medicines